Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - CNBC
AI Summary1 min read
TL;DR
Pfizer's mid-stage trial shows its monthly obesity injection leads to significant weight loss, with patients losing up to 12% of their weight. The drug demonstrates robust results as a potential long-term treatment option.
Tags
Pfizerobesity injectionmonthly treatmentweight lossclinical trial
- Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial CNBC
- Pfizer unveils data on Metsera drug statnews.com
- Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial Business Wire
- Pfizer flags promising obesity drug data, fourth-quarter results top Street view Reuters
- Pfizer study finds patients lose up to 12% of their weight after taking once-a-month drug MarketWatch